Policies that outline what is and isn't allowed on the Facebook app.
Policies for ad content and business assets.
Other policies that apply to Meta technologies.
How we update our policies, measure results, work with others, and more.
How we help prevent interference, empower people to vote and more.
How we work with independent fact-checkers, and more, to identify and take action on misinformation.
How we assess content for newsworthiness.
How we reduce problematic content in News Feed.
Quarterly report on how well we're doing at enforcing our policies on the Facebook app and Instagram.
Report on how well we're helping people protect their intellectual property.
Report on government request for people's data.
Report on when we restrict content that's reported to us as violating local law.
Report on intentional internet restrictions that limit people's ability to access the internet.
Quarterly report on what people see on Facebook, including the content that receives the widest distribution during the quarter.
Download current and past regulatory reports for Facebook and Instagram.
MAY 25, 2023
Today, the Oversight Board selected a case referred by Meta regarding an Instagram post describing a user’s experience with ketamine for the medical treatment of anxiety and depression by medical professionals. The user praises their experience, describing the altered mental state they entered as a result of the substance as well as their support for the use of psychedelics in treating mental health conditions.
Meta determined that this content did not violate our policy on Restricted Goods and Services, as laid out in our Instagram Community Guidelines and Facebook Community Standards and left the content up.
Meta referred this case to the board because we found it significant and difficult as it creates tension between our values of safety, voice and dignity.
While Meta typically does not allow content that “admits to personal use” or “promotes” non-medical drugs (the definition for which includes substances “used to achieve a high” or altered mental state), we allow for broader discussion as it relates to pharmaceutical drugs which are defined as “drugs that require a prescription or medical professionals to administer.” These two definitions in our policies can conflict when a drug is legally administered by medical professionals for treating mental illness in which an altered mental state can be a goal. In this instance, we determined the admission and promotion of ketamine use as a medically-administered pharmaceutical is allowed because it is in line with our overall policy of promoting discussion about medical treatment.
We will implement the board’s decision once it has finished deliberating, and we will update this post accordingly. Please see the board’s website for the decision when they issue it.